Potential gains in life expectancy from reducing amenable mortality among people diagnosed with serious mental illness in the United Kingdom

Background To estimate the potential gain in life expectancy from addressing modifiable risk factors for all-cause mortality (excluding suicide and deaths from accidents or violence) across specific serious mental illness (SMI) subgroups, namely schizophrenia, schizoaffective disorders, and bipolar disorders in a Western population. Methods We have used relative risks from recent meta-analyses to estimate the population attribution fraction (PAF) due to specific modifiable risk factors known to be associated with all-cause mortality within SMI. The potential gain in life expectancy at birth, age 50 and age 65 years were assessed by estimating the combined effect of modifiable risk factors from different contextual levels (behavioural, healthcare, social) and accounting for the effectiveness of existing interventions tackling these factors. Projections for annual gain in life expectancy at birth during a two-decade was estimated using the Annual Percentage Change (APC) formula. The predicted estimates were based on mortality rates for year 2014–2015. Results Based on the effectiveness of existing interventions targeting these modifiable risk factors, we estimated potential gain in life expectancy at birth of four (bipolar disorders), six (schizoaffective disorders), or seven years (schizophrenia). The gain in life expectancy at age 50 years was three (bipolar disorders) or five (schizophrenia and schizoaffective disorders) years. The projected gain in life expectancy at age 65 years was three (bipolar disorders) or four (schizophrenia and schizoaffective disorders) years. Conclusions The implementation of existing interventions targeting modifiable risk factors could narrow the current mortality gap between the general and the SMI populations by 24% (men) to 28% (women). These projections represent ideal circumstances and without the limitation of overestimation which often comes with PAFs.

[1]  C. Hewitt,et al.  Smoking cessation in severe mental illness: combined long-term quit rates from the UK SCIMITAR trials programme , 2019, The British Journal of Psychiatry.

[2]  P. Andersen,et al.  Cause-specific life years lost among persons diagnosed with schizophrenia: Is it getting better or worse? , 2019, Schizophrenia Research.

[3]  F. Hu,et al.  The association between BMI and mortality: implications for obesity prevention. , 2018, The lancet. Diabetes & endocrinology.

[4]  V. Raleigh.  Stalling life expectancy in the UK , 2018, British Medical Journal.

[5]  David McDaid,et al.  Preventive strategies for mental health. , 2018, The lancet. Psychiatry.

[6]  U. Werneke,et al.  Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study , 2018, BMC Psychiatry.

[7]  A. Tanskanen,et al.  Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia , 2017, Schizophrenia Research.

[8]  K. Walters,et al.  Statin prescribing for prevention of cardiovascular disease amongst people with severe mental illness: Cohort study in UK primary care , 2017, Schizophrenia Research.

[9]  Per Kragh Andersen,et al.  Life years lost among patients with a given disease , 2017, Statistics in medicine.

[10]  G. Tew,et al.  Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis , 2017, BMC Psychiatry.

[11]  Paolo Santonastaso,et al.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls , 2017, World psychiatry : official journal of the World Psychiatric Association.

[12]  R. Dutta,et al.  Contributions of specific causes of death to lost life expectancy in severe mental illness , 2017, European Psychiatry.

[13]  Guangquan Li,et al.  Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble , 2017, The Lancet.

[14]  Steve Kisely,et al.  درمان اجباری مدنی و غیر داوطلبانه در بیماران سرپایی برای افراد مبتلا به اختلالات شدید روانی , 2017 .

[15]  S. Kisely,et al.  Compulsory community and involuntary outpatient treatment for people with severe mental disorders. , 2017, The Cochrane database of systematic reviews.

[16]  W. Hall,et al.  The challenge of reducing smoking in people with serious mental illness. , 2016, The Lancet. Respiratory medicine.

[17]  G. Thornicroft,et al.  Qualitative analysis of mental health service users’ reported experiences of discrimination , 2016, Acta psychiatrica Scandinavica.

[18]  K. Schnell,et al.  Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder , 2016, PloS one.

[19]  D. Schillinger,et al.  Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review , 2016, Journal of General Internal Medicine.

[20]  R. Swaminathan,et al.  Comparison of Trends in Incidence, Revascularization, and In-Hospital Mortality in ST-Elevation Myocardial Infarction in Patients With Versus Without Severe Mental Illness. , 2016, The American journal of cardiology.

[21]  T. Brugha,et al.  Reducing excess mortality due to chronic disease in people with severe mental illness: Meta-review of health interventions , 2016, British Journal of Psychiatry.

[22]  J. Veerman,et al.  Population attributable fraction: names, types and issues with incorrect interpretation of relative risks , 2016, British Journal of Sports Medicine.

[23]  C. Baethge,et al.  Characteristics and heterogeneity of schizoaffective disorder compared with unipolar depression and schizophrenia - a systematic literature review and meta-analysis. , 2016, Journal of affective disorders.

[24]  Louise Marston,et al.  Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population‐based UK cohort study using electronic health records , 2016, World psychiatry : official journal of the World Psychiatric Association.

[25]  M. Olfson,et al.  Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. , 2015, The American journal of psychiatry.

[26]  M. Olfson,et al.  Premature Mortality Among Adults With Schizophrenia in the United States. , 2015, JAMA psychiatry.

[27]  J. Reilly,et al.  From efficacy to effectiveness in smoking cessation in severe mental illness , 2015, BMJ : British Medical Journal.

[28]  J. Leon,et al.  A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults , 2015, Bipolar disorders.

[29]  P. Andersen,et al.  Causes of decreased life expectancy over the life span in bipolar disorder. , 2015, Journal of affective disorders.

[30]  N. Best,et al.  The future of life expectancy and life expectancy inequalities in England and Wales: Bayesian spatiotemporal forecasting , 2015, The Lancet.

[31]  S. Stewart-Brown,et al.  Socioeconomic gradients and mental health: implications for public health. , 2015, The British journal of psychiatry : the journal of mental science.

[32]  R. Stewart,et al.  Delays before Diagnosis and Initiation of Treatment in Patients Presenting to Mental Health Services with Bipolar Disorder , 2015, PloS one.

[33]  C. Hewitt,et al.  Bespoke smoking cessation for people with severe mental ill health (SCIMITAR): a pilot randomised controlled trial. , 2015, The lancet. Psychiatry.

[34]  E. Mayo-Wilson,et al.  Interventions to improve the experience of caring for people with severe mental illness: systematic review and meta-analysis , 2015, British Journal of Psychiatry.

[35]  K. Walters,et al.  Meta-analysis A systematic review and meta-analysis of premature mortality in bipolar affective disorder , 2015 .

[36]  K. Wilson,et al.  Improving the estimation of the burden of risk factors: an illustrative comparison of methods to measure smoking-attributable mortality , 2015, Population Health Metrics.

[37]  Matthew Broadbent,et al.  The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders , 2014, Schizophrenia bulletin.

[38]  F. Matcham,et al.  A pilot randomized controlled trial to increase smoking cessation by maintaining National Health Service Stop Smoking Service attendance. , 2014, British journal of health psychology.

[39]  B. Leff,et al.  Multiple Chronic Conditions and Life Expectancy: A Life Table Analysis , 2014, Medical care.

[40]  R. Whitley,et al.  Stigma, agency and recovery amongst people with severe mental illness. , 2014, Social science & medicine.

[41]  Caroline R Richardson,et al.  Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry. , 2014, Journal of affective disorders.

[42]  S. Parikh,et al.  Stigma and bipolar disorder: a review of the literature. , 2013, Journal of affective disorders.

[43]  C. Correll,et al.  Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions , 2013, World psychiatry : official journal of the World Psychiatric Association.

[44]  G. Thornicroft.  Premature death among people with mental illness , 2013, BMJ.

[45]  R. Baldessarini,et al.  Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder , 2013, Bipolar disorders.

[46]  A. Kriska,et al.  Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders (WAIST Study) , 2013, Schizophrenia Research.

[47]  D. Vancampfort,et al.  Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. , 2013, Schizophrenia bulletin.

[48]  Marc De Hert,et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.

[49]  J. S. Siegel.  The Demography and Epidemiology of Human Health and Aging , 2011 .

[50]  Andrea C. Fernandes,et al.  Associations between substance use disorder sub-groups, life expectancy and all-cause mortality in a large British specialist mental healthcare service. , 2011, Drug and alcohol dependence.

[51]  H. Möller,et al.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level , 2011, World psychiatry : official journal of the World Psychiatric Association.

[52]  A. Mitchell,et al.  Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis , 2011, British Journal of Psychiatry.

[53]  Andrea C. Fernandes,et al.  Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London , 2011, PloS one.

[54]  M. Beary,et al.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? , 2010, Journal of psychopharmacology.

[55]  Andrea C. Fernandes,et al.  All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study , 2010, BMC psychiatry.

[56]  L. McNally,et al.  The Delivery of Stop Smoking Support to People with Mental Health Conditions: A Survey of NHS Stop Smoking Services , 2010, BMC health services research.

[57]  Antti Tanskanen,et al.  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) , 2009, The Lancet.

[58]  A. Fagiolini,et al.  The effects of undertreated chronic medical illnesses in patients with severe mental disorders. , 2009, The Journal of clinical psychiatry.

[59]  Esben Agerbo,et al.  Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. , 2009, The Journal of clinical psychiatry.

[60]  G. L’italien,et al.  UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[61]  J. Lieberman,et al.  Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study , 2008, Schizophrenia Research.

[62]  V. Peralta,et al.  Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach. , 2008, Journal of affective disorders.

[63]  Tina Sacks,et al.  Targeting health disparities: a model linking upstream determinants to downstream interventions. , 2008, Health affairs.

[64]  I. Nazareth,et al.  Physical activity, dietary habits and Coronary Heart Disease risk factor knowledge amongst people with severe mental illness , 2007, Social Psychiatry and Psychiatric Epidemiology.

[65]  Nathaniel G. Hurwitz,et al.  Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease – there is no schizoaffective disorder , 2007, Current opinion in psychiatry.

[66]  J. Bobes,et al.  Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study , 2007, Schizophrenia Research.

[67]  Katherine Perryman,et al.  A survey of staff attitudes to smoking-related policy and intervention in psychiatric and general health care settings. , 2006, Journal of public health.

[68]  T. George,et al.  Co-morbidity of smoking in patients with psychiatric and substance use disorders. , 2005, The American journal on addictions.

[69]  G. Cassano,et al.  Cross-sectional similarities and differences between schizophrenia, schizoaffective disorder and mania or mixed mania with mood-incongruent psychotic features , 2004, European Psychiatry.

[70]  Louise C Hawkley,et al.  Loneliness and pathways to disease , 2003, Brain, Behavior, and Immunity.

[71]  J. Gundgaard,et al.  Increased intake of fruit and vegetables: estimation of impact in terms of life expectancy and healthcare costs† , 2003, Public Health Nutrition.

[72]  Robert Rosenheck,et al.  Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. , 2002, The American journal of psychiatry.

[73]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[74]  秀樹 林谷,et al.  The life table and its applications , 1995 .

[75]  C. L. Chiang,et al.  The life table and its applications , 1985 .